Brief: Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million
11/03/2026 20:05
Mar 11 (Reuters) - Tenaya Therapeutics Q4 operating expenses USD 20.775 million. Q4 operating income USD -20.775 million Q4 pretax profit USD -20.175 million vs. IBES estimate USD -22 million Q4 basic EPS USD -0.12
Recent news on Tenaya Therapeutics
See all newsTenaya Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tenaya Therapeutics Q2 net loss widens on impairment charge
Brief: Tenaya Therapeutics Q2 Net Income USD -43.393 Million
Brief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401